Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

26-07-2022 | Gastrectomy | ASO Research Letter

Soluble E-Cadherin as a Potential Biomarker in Hereditary Diffuse Gastric Cancer Syndrome

Authors: Martha E. Teke, MD, Lauren A. Gamble, MD, Sarah G. Samaranayake, MS, Benjamin L. Green, MD, Areeba Saif, MD, Jonathan M. Hernandez, MD, Jeremy L. Davis, MD

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Excerpt

Hereditary diffuse gastric cancer (HDGC) syndrome, caused by inactivating germline variants in the CDH1 tumor suppressor gene, confers an elevated lifetime gastric cancer risk of 25–42%.1 Multifocal, occult SRC carcinomas are identified in nearly all prophylactic total gastrectomy explants from asymptomatic CDH1 variant carriers.2 These intramucosal SRC foci exhibit indolent behavior, and the specific molecular alterations underpinning cancer progression are yet to be unveiled.1 As such, risk-reducing total gastrectomy is recommended for all germline CDH1 variant carriers with family history of diffuse gastric cancer (DGC) starting at age 20 years.3 Total gastrectomy carries significant risk, potential morbidity, and lifestyle change. Therefore, a critical need exists for early, noninvasive means of prognostication for this rare patient population. …
Literature
1.
Gamble LA, Heller T, Davis JL. Hereditary diffuse gastric cancer syndrome and the role of CDH1: a review. JAMA Surg. 2021;156(4):387–92.CrossRefPubMed
2.
Carneiro P, Fernandes MS, Figueiredo J, et al. E-cadherin dysfunction in gastric cancer—cellular consequences, clinical applications and open questions. FEBS Lett. 2012;586(18):2981–9.CrossRefPubMed
3.
4.
5.
Zhao H, Hu H, Chen B, et al. Overview on the role of E-Cadherin in gastric cancer: dysregulation and clinical implications. Front Mol Biosci. 2021;8:689139.CrossRefPubMedPubMedCentral
Metadata
Title
Soluble E-Cadherin as a Potential Biomarker in Hereditary Diffuse Gastric Cancer Syndrome
Authors
Martha E. Teke, MD
Lauren A. Gamble, MD
Sarah G. Samaranayake, MS
Benjamin L. Green, MD
Areeba Saif, MD
Jonathan M. Hernandez, MD
Jeremy L. Davis, MD
Publication date
26-07-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12288-4

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

ASO Author Reflections

ASO Author Reflections: How Immunotherapy Could Change the Management of Responsive Solid Tumors

ASO Visual Abstract

ASO Visual Abstract: Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver

ASO Author Reflections

ASO Author Reflections: Epidural Analgesia Decreases In-Hospital Mortality, Respiratory Complications, and Anastomotic Leakage After Minimally Invasive Esophagectomy for Esophageal Cancer

ASO Author Reflections

ASO Author Reflections: Identification of High-Performing Veterans Affairs Health System Regions to Improve Patient Outcomes of Veterans with Hepatocellular Carcinoma

ASO Author Reflections

ASO Author Reflections: The Role of CEA Optimizing Perioperative Treatments for Colorectal Cancer with Liver Metastases

ASO Visual Abstract

ASO Visual Abstract: Very Early Recurrence After Curative-Intent Surgery for Gastric Adenocarcinoma